8422085|t|A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
8422085|a|The potential efficacy of oral l-deprenyl (5 mg b.i.d.) added to the regimen of 10 patients with Alzheimer's disease receiving either tacrine or physostigmine was assessed in a double-blind, placebo-controlled, 4-week, two-period crossover pilot study. l-Deprenyl was associated with significant improvement in scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale, suggesting possible additive effects of l-deprenyl to the effects of cholinesterase inhibitors.
8422085	40	50	l-deprenyl	Chemical	MESH:D012642
8422085	52	62	selegiline	Chemical	MESH:D012642
8422085	78	92	cholinesterase	Gene	590
8422085	106	125	Alzheimer's disease	Disease	MESH:D000544
8422085	158	168	l-deprenyl	Chemical	MESH:D012642
8422085	210	218	patients	Species	9606
8422085	224	243	Alzheimer's disease	Disease	MESH:D000544
8422085	261	268	tacrine	Chemical	MESH:D013619
8422085	272	285	physostigmine	Chemical	MESH:D010830
8422085	380	390	l-Deprenyl	Chemical	MESH:D012642
8422085	478	497	Alzheimer's Disease	Disease	MESH:D000544
8422085	556	566	l-deprenyl	Chemical	MESH:D012642
8422085	585	599	cholinesterase	Gene	590
8422085	Negative_Correlation	MESH:D012642	MESH:D000544
8422085	Negative_Correlation	MESH:D013619	MESH:D000544
8422085	Association	MESH:D000544	590
8422085	Cotreatment	MESH:D012642	MESH:D013619
8422085	Negative_Correlation	MESH:D012642	590
8422085	Negative_Correlation	MESH:D010830	MESH:D000544

